What is cancer anorexia-cachexia syndrome? A historical perspective

被引:1
|
作者
Bennani-Baiti, N. [1 ]
Walsh, D. [2 ]
机构
[1] Cleveland Clin, Sect Palliat Med & Support Oncol, Taussig Canc Ctr, Cleveland, OH 44106 USA
[2] Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Taussig Canc Ctr, Cleveland, OH 44106 USA
关键词
Anorexia; cachexia; cancer; definition; syndrome;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer anorexia-cachexia syndrome (CACS) is a lethal but poorly defined involuntary wasting disorder. Loss of skeletal muscle and fat distinguishes it from starvation. Cachexia has been described as a clinical syndrome since ancient times, and the poor prognosis has long been acknowledged. In this article we have reviewed historical perspectives on cancer cachexia, and commented on modern definitions. In cancer cachexia, most historical descriptions included anorexia, wasting and a pale complexion. Other associated symptoms, such as fatigue, early satiety and taste changes, were inconsistently described. Newer descriptions have not significantly expanded the clinical picture. Today, there is still no consensus definition, hindering research on early diagnosis and effective therapy. The language descriptors used to characterise the syndrome are important. For example, the word 'cachexia' itself may mislead; perhaps cancer-related wasting syndrome is more accurate. Cancer anorexia-cachexia syndrome is a disorder associated with high morbidity and mortality, and deserves greater attention in both clinical and translational research.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 50 条
  • [21] Cancer anorexia-cachexia syndrome - Psychological effect on the patient and family
    McClement, S
    JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING, 2005, 32 (04) : 264 - 268
  • [22] Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome
    Patra, Surajeet K.
    Arora, Sarika
    CLINICA CHIMICA ACTA, 2012, 413 (13-14) : 1025 - 1034
  • [23] Nutrition support and pharmacotherapy in cancer patients with anorexia-cachexia syndrome
    Snegovoy, Anton
    Manzuk, Ludmila
    Kanagavel, Dheepak
    Blokhin, N. N.
    ANNALS OF ONCOLOGY, 2007, 18 : 195 - 195
  • [24] Cancer anorexia-cachexia syndrome: Current issues in research and management
    Inui, A
    CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (02) : 72 - 91
  • [25] SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
    Rivas, Ainara Soria
    Alvarez, Yolanda Escobar
    Cordellat, Ana Blasco
    Tarruella, Margarita Majem
    Mata, Kevin Molina
    Sanchez, M. del Mar Munoz
    de la Camara, Marta Motilla
    Poves, Marta Zafra
    Zambrano, Carmen Beato
    Gutierrez, Luis Cabezon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (11): : 2866 - 2876
  • [26] Pharmacological therapy of cancer anorexia-cachexia
    Cardona, D.
    NUTRICION HOSPITALARIA, 2006, 21 : 17 - 26
  • [27] BRAIN TRYPTOPHAN AND THE NEOPLASTIC ANOREXIA-CACHEXIA SYNDROME
    KRAUSE, R
    JAMES, JH
    ZIPARO, V
    FISCHER, JE
    CANCER, 1979, 44 (03) : 1003 - 1008
  • [28] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins, C.
    PHARMACY WORLD & SCIENCE, 2008, 30 (04): : 420 - 420
  • [29] New drugs for the anorexia-cachexia syndrome.
    Davis M.P.
    Current Oncology Reports, 2002, 4 (3) : 264 - 274
  • [30] Megestrol acetate for the treatment of anorexia-cachexia syndrome
    Berenstein, EG
    Ortiz, Z
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02):